CVS · 10-Q · 2026Q3

CVS HEALTH Corp

Filed 2026-11-04 · Consumer · View original filing on EDGAR

Everything CVS's SEC filings said, ranked

Ranked Events

• Cash Flow and LiquidityImportance 69 · Surprise 64
  Cash and cash equivalents totaled approximately $11.7 billion at September 30, 2026, including approximately $5.9 billion held by the parent company or nonrestricted subsidiaries. Nine-month operating cash flow rose…
• Strategic Business SeparationImportance 65 · Surprise 60
  On November 4, 2026, CVS Health announced an intended separation into two independent, publicly traded companies in a transaction intended to be tax-free for U.S. federal income tax purposes. The healthcare solutions…
• Operating Income and MarginsImportance 63 · Surprise 64
  Consolidated operating income was $12.949 billion for the nine months ended September 30, 2026, compared with $2.548 billion in 2025, an increase of $10.401 billion, or 408.2%; third-quarter operating income was $3.566…
• Segment Revenue PerformanceImportance 61 · Surprise 66
  Health Care Benefits’ nine-month Government premium revenue increased $7.585 billion, or 9.9%, to $84.385 billion, while Commercial premium revenue declined $4.836 billion, or 20.2%, to $19.095 billion. The Commercial…
• State Non-Income Tax ChangeImportance 48 · Surprise 74
  A retroactive change in a state law related to non-income taxes contributed to CVS Health’s increased adjusted operating loss for the nine months ended September 30, 2026. The filing does not identify the state, the…
• Health Services Pharmacy DemandImportance 42 · Surprise 40
  Health Services revenue grew 9.5% in the third quarter and 10.6% in the first nine months of 2026, primarily from pharmacy drug mix and brand inflation, partly offset by continued pharmacy client price improvements.…
• PBM Rebate and Pricing PressureImportance 38 · Surprise 24
  CVS continues to pass a larger portion of pharmaceutical manufacturer rebates, fees and discounts to clients and typically offers minimum pricing guarantees that it may not achieve. Manufacturers are also applying…
• Income Tax Rate ChangesImportance 37 · Surprise 46
  The effective income tax rate was 23.8% for the third quarter of 2026, compared with negative 14.6% in the third quarter of 2025. For the first nine months of 2026, the effective rate was 24.5%, compared with 252.8% in…
• Medical Cost Trend / Benefit RatioImportance 37 · Surprise 32
  Health Care Benefits’ medical benefit ratio (MBR) improved to 91.3% in the third quarter of 2026 from 92.8% a year earlier, a 150-basis-point decrease driven primarily by improved underlying Government business…
• Revenue Performance and MixImportance 36 · Surprise 14
  Consolidated revenue for the nine months ended September 30, 2026 rose $18.547 billion, or 6.3%, to $314.921 billion; third-quarter revenue rose $5.528 billion, or 5.4%, to $108.399 billion. Nine-month growth was led…
• PBM Legislative RestrictionsImportance 35 · Surprise 24
  The filing reports that legislation and regulations seeking comprehensive regulation of pharmacy benefit manager activities have been proposed or enacted in a majority of U.S. states and at the federal level. Some…
• Segment ProfitabilityImportance 34 · Surprise 38
  Corporate/Other total revenues increased $72 million, or 54.1%, in the three months ended September 30, 2026, and $116 million, or 32.0%, in the nine months, primarily reflecting improved net investment income. The…
• Omnicare Litigation ResolutionImportance 34 · Surprise 42
  In the third quarter of 2026, CVS Health recorded an estimated contingent guarantee liability tied to agreements to resolve litigation and Chapter 11 bankruptcy matters involving Omnicare, LLC and certain subsidiaries.…
• Medicare Advantage Payment OutlookImportance 33 · Surprise 32
  On April 6, 2026, the U.S. Centers for Medicare & Medicaid Services issued final 2027 Medicare Advantage payment rates, which imply an average industry revenue increase of 2.48%, excluding CMS’s estimate of Medicare…
• Legacy Litigation ChargesImportance 30 · Surprise 42
  CVS Health recorded $1.2 billion in legacy litigation charges in the nine months ended September 30, 2025, related to two court decisions associated with its past business practices. The charges were reflected in…
• DividendsImportance 27 · Surprise 6
  CVS declared a quarterly cash dividend of $0.665 per share in the three months ended September 30, 2026, unchanged from the prior-year quarter. Dividends declared totaled $1.995 per share in the nine months ended…
• Medical Membership TrendsImportance 25 · Surprise 32
  Health Care Benefits medical membership was 26.1 million at September 30, 2026, down approximately 600,000 from a year earlier. CVS attributed the decline to its exit from the individual exchange business in 2026,…
• Retail Pharmacy DemandImportance 25 · Surprise 32
  Pharmacy & Consumer Wellness revenue declined $716 million, or 2.0%, to $35.498 billion in the third quarter of 2026, while pharmacy same-store sales fell 0.6%. Regulatory-related drug price reductions, generic drug…
• Operating Expense TrendsImportance 21 · Surprise 32
  Consolidated operating expenses were $33.322 billion for the nine months ended September 30, 2026, down $200 million, or 0.6%, from 2025. The decrease primarily reflected the absence of $1.2 billion in legacy…
• Medical Utilization PressureImportance 20 · Surprise 24
  Utilization remained elevated in the third quarter of 2026. CVS said utilization above current elevated levels could pressure the Health Care Benefits segment and health care delivery assets in Health Services during…

Revenue by Product (in millions)